-transparent.png){kind=logo}
Lymphocyte infiltration into a tumor has been regarded as an expression of host immunity against cancer, but tumor-infiltrating lymphocytes (TIL) have little or no cytotoxicity. This study examined two different approaches to augment this low cytotoxicity. Firstly, biological response modifiers (OK-432, PSK) were injected into gastric cancer intralesionally. Intralesional injection of OK-432 or PSK significantly augmented the cytotoxicity of TIL. By the injection of OK-432, the ratio of OKT8-, Leu7-positive cells were increased in the TIL subset. In the second approach, TIL of gastric or pulmonary cancer patients were cultured with interleukin-2 (IL-2) in vitro. Co-culturing with IL-2 augmented the low cytotoxicity of TIL, and broad-reactive lymphokine-activated killer (LAK) cells were generated from TIL.
K Gotoh, and
A Gouchi, and
Y Akura, and
N Tanaka, and
K Orita
January 1990,
Anticancer research,
K Gotoh, and
A Gouchi, and
Y Akura, and
N Tanaka, and
K Orita
December 1985,
Nihon Geka Gakkai zasshi,
K Gotoh, and
A Gouchi, and
Y Akura, and
N Tanaka, and
K Orita
January 1988,
Natural immunity and cell growth regulation,
K Gotoh, and
A Gouchi, and
Y Akura, and
N Tanaka, and
K Orita
February 2003,
International journal of oncology,
K Gotoh, and
A Gouchi, and
Y Akura, and
N Tanaka, and
K Orita
September 1983,
Gan to kagaku ryoho. Cancer & chemotherapy,
K Gotoh, and
A Gouchi, and
Y Akura, and
N Tanaka, and
K Orita
June 1994,
Clinical and experimental immunology,
K Gotoh, and
A Gouchi, and
Y Akura, and
N Tanaka, and
K Orita
December 1989,
Japanese journal of cancer research : Gann,
K Gotoh, and
A Gouchi, and
Y Akura, and
N Tanaka, and
K Orita
September 1991,
International journal of cancer,
K Gotoh, and
A Gouchi, and
Y Akura, and
N Tanaka, and
K Orita
January 1987,
Cancer detection and prevention. Supplement : official publication of the International Society for Preventive Oncology, Inc,
K Gotoh, and
A Gouchi, and
Y Akura, and
N Tanaka, and
K Orita
January 1986,
Cancer immunology, immunotherapy : CII,
